ALBT - Avalon GloboCare Corp Price-to-Projected Revenue Ratio

Corporate emblem and logo of avalon-globocare.com (ALBT)

The lack of recurring revenue due to a focus on regenerative medicine makes Avalon GloboCare (ALBT) stock dynamics dependent on external funding, and by tracking the business's future P/S on GURU.Markets, we note that the indicator value reaches 3.90. Avalon GloboCare (ALBT) management effectively combines clinical expertise with corporate governance. The holding company has currently paused mergers to monetize its existing laboratory networks.

ALBT Avalon GloboCare Corporation: Market Cap to Projected Revenue in the range 04/28/2023 - 07/22/2026

Analytical breakdowns and data insights for company Avalon GloboCare Corp (ALBT)

Summary company analytics:ALBT (Avalon GloboCare Corporation)
Product sample of Avalon GloboCare Corp.

The forward P/S reflects the ratio of Avalon GloboCare (ALBT) market capitalization to projected annual revenue, where the projected P/S trend allows for an assessment of the premium paid for expected cash flows. A high multiple here is justified by the inelastic demand for the unique QTY protein code, which provides the company with pricing power and fundamental business stability during its expansion into cancer therapy.

Competitor analysis

Forward P/S Multiple HCA (HCA Healthcare, Inc.)|Price to Expected Revenue Ratio THC (Tenet Healthcare)|FMS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio solventum.com|EHC: Forward P/S Multiple|UHS - Market Cap to Expected Sales Ratio|DVA (DaVita Corp) - Forward P/S Multiple|RDNT: Forward Price to Sales|Forward P/S Multiple OPCH|SGRY (surgerypartners.com) - Forward Price to Sales|Forward P/S Multiple PINC (Premier Inc)|National Vision - Price-to-Projected Revenue Ratio|PGNY - Price-to-Projected Revenue Ratio|ARDT - Forward P/S Multiple|SEM: Forward P/S Multiple|astranahealth.com (ASTH) - Forward P/S Multiple|MD (mednax.com) - Forward P/S Multiple|Forward P/S Multiple usph.com|Forward P/S Multiple PNTG|Market Cap to Expected Sales Ratio Organogenesis Holdings|Forward P/S Multiple NUTX (nutexhealth.com)|Auna SA (AUNA) - Market Cap to Future Revenue Ratio|SBC: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Jeuveau EOLS|CYH (Community Health Systems Inc) - Forward Price-to-Revenue Multiple|SKIN: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple MDWD|BTMD: Forward Price to Sales|Price-to-Projected Revenue Ratio The Joint Corporation (JYNT)|Forward P/S Multiple DocGo Inc (DCGO)|Forward Price to Sales P3 Health Partners, Inc.|Market Cap to Expected Sales Ratio gaintherapeutics.com (GANX)|EUDA: Forward Price-to-Revenue Multiple|BMGL: Price-to-Projected Revenue Ratio|collplant.com (CLGN) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Cuprina Holdings|CCM (concordmedical.com) - Forward P/S Multiple|Forward P/S Multiple ASHS|Price-to-Projected Revenue Ratio MEDIROM (MRM)|Market Cap to Expected Sales Ratio DIH Holding|Forward P/S Multiple XAGE (carmellcosmetics.com)|NIVF: Market Cap to Projected Revenue|ATIP: Forward Price-to-Revenue Multiple|CareMax Medical Group - Price to Expected Revenue Ratio|Kindly MD (KDLY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MODV|Price-to-Projected Revenue Ratio Novo Integrated Sciences Corp|Market Cap to Future Revenue Ratio SunLink Health Systems SSY|Price-to-Projected Revenue Ratio IMAC Corp (BACK)